Navigation Links
Anthera Pharmaceuticals to Present at Annual Piper Jaffray Healthcare Conference
Date:11/27/2013

HAYWARD, Calif., Nov. 27, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, announced today that Paul F. Truex, President and Chief Executive Officer, and May Liu, Senior Vice President of Finance and Administration, will present a corporate update at the 2013 Annual Piper Jaffray Healthcare Conference.

Anthera will present at 4:00PM ET, December 3rd, at the Palace Hotel in New York City.

About Blisibimod

Anthera is developing blisibimod, a selective inhibitor of B-cell activating factor (BAFF), to explore its clinical utility in various autoimmune diseases including systemic lupus erythematosus (SLE) and IgA nephropathy. Blisibimod is a novel fusion protein, or peptibody, and is distinct from an antibody. Anthera owns worldwide rights to blisibimod in all potential indications. BAFF, also known as BLyS (B lymphocyte stimulator), is a tumor necrosis family member and is critical to the development, maintenance and survival of B-cells. B-cells represent a critical component of human immune response to infection and other pathogens. However, abnormal elevations of B-cells and BAFF may lead to an overactive immune response which may damage normal healthy tissues and organ systems. Multiple clinical studies with BAFF antagonists have reported the potential benefit of BAFF inhibitors in treating patients with lupus and rheumatoid arthritis.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases. Anthera's Phase 3 development product candidate, blisibimod, targets elevated levels of B-
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Anthera Pharmaceuticals Reports 2013 Third Quarter Financial Results, Clinical and Regulatory Update
2. Anthera Pharmaceuticals Announces Emerging Data from Phase 2 Open-Label Extension Study to be Presented at the ACR/ARHP 2013 Annual Scientific Meeting
3. Anthera Pharmaceuticals Reports 2013 Second Quarter Financial Results
4. Anthera Announces Initiation of BRIGHT-SC Phase 2 Clinical Study in IgA Nephropathy with Blisibimod
5. Anthera Pharmaceuticals Announces Receipt of Nasdaq Notice
6. Anthera Pharmaceuticals Announces Personnel Changes
7. Anthera Pharmaceuticals to Present at Annual Jefferies Healthcare Conference
8. Anthera Pharmaceuticals Reports 2013 First Quarter Financial Results
9. Anthera Pharmaceuticals Announces Additional Data from Phase 2b PEARL-SC Blisibimod Study
10. Anthera Refinances Existing Debt with New $20 Million Credit Facility and Secures $18.5 Million Committed Equity Financing Facility
11. Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)...  Uroplasty, Inc. (NASDAQ: UPI ), a medical ... products to treat voiding dysfunctions, today announced that it ... Tuesday, March 10, 2015. Rob Kill , President ... Officer, will present at 4:00 p.m. Pacific Time and ... at the Ritz Carlton in Laguna Niguel, ...
(Date:2/27/2015)... 27, 2015  Two mass spectrometry technologies ... as their effectiveness is established, according to ... Information says that while mass spectrometry (mass ... tool in proteomic biomarker discovery and validation, ... traditional techniques has struggled to elucidate molecular ...
(Date:2/26/2015)... , Feb. 26, 2015  Tandem Diabetes Care®, Inc. ... and manufacturer of the t:slim® and t:flex™ Insulin Pumps, ... of 5,250,000 shares of its common stock at a ... net proceeds to Tandem from this offering are expected ... commissions and other estimated offering expenses payable by Tandem. ...
Breaking Medicine Technology:Uroplasty to Participate in the 27th Annual ROTH Conference 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 3Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 3
... Jan. 17, 2012 To address the growing need ... with the automation of routine clinical laboratory assays, ... Tecan Group (SIX Swiss Exchange: TECN) today entered into ... handling platform with Waters® ACQUITY® TQD liquid ...
... RIVER EDGE, N.J., Jan. 17, 2012  Nephros, Inc. (OTC ... developing and marketing filtration products for therapeutic applications, infection ... 16, 2012, Nephros received a payment of euro 750,000 ... Under the terms of the license agreement ...
Cached Medicine Technology:Waters and Tecan Sign Agreement for Clinical Assay Platform 2Waters and Tecan Sign Agreement for Clinical Assay Platform 3Nephros Receives Euro 750,000 Payment from Bellco S.r.l. 2Nephros Receives Euro 750,000 Payment from Bellco S.r.l. 3Nephros Receives Euro 750,000 Payment from Bellco S.r.l. 4
(Date:2/28/2015)... 28, 2015 Dr. Perry Patel ... area residents, recently announced a special offer for the ... treatment option for new and established patients at his Pismo ... a bright, white smile, Dr. Patel and his staff ... marked down from the regular price of $450. , ...
(Date:2/28/2015)... February 28, 2015 Kaylie Corrigan, Outdoor ... treatment center , and current student obtaining her Masters ... implemented a weekly forum in psychoeducation on substance use ... Flagstaff, AZ as part of her studies. , “Even ... for support and counseling at the high school and ...
(Date:2/28/2015)... ON (PRWEB) February 28, 2015 The ... to announce that they have officially relaunched their website. ... more user-friendly, but it contains a new section about ... access to read the full biographies of each Friedman ... portion of the website was designed to provide our ...
(Date:2/28/2015)... Javon Bea Mercy Health System CEO ... stroke capable by the State of Illinois, enabling potential ... Harvard Hospital. , The hospital was required to submit ... treat stroke according to national standards of care for ... to bypass hospitals not designated as an Emergent Stroke ...
(Date:2/28/2015)... TN: MedixSafe has retracted a previous announcement from ... named Guardian 2. The correct product name is ... that significantly increases the complexity of security credentials. ... provides fast and easy access for both the ... with Vanguard technology tracks inventory by time, ...
Breaking Medicine News(10 mins):Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2Health News:Staff at Arizona Drug Addiction Treatment Center Starts Teen Sobriety Support Group at Local High School 2Health News:Friedman Dental Group Announces Their Updated Website 2Health News:Mercy Harvard Hospital Recognized as Leader in Stroke Care - Javon Bea 2Health News:New Name Announced For Newest MedixSafe Readers – MedixSafe Vanguard 2
... CARLOS, Calif., April 9, 2008 Nuvelo,Inc. (Nasdaq: ... evaluating the,mechanism of action and therapeutic potential of ... preclinical data,evaluating recombinant nematode anticoagulant protein c2 (rNAPc2) ... at the 2008 American,Association for Cancer Research (AACR) ...
... UCN, Inc.,(Nasdaq: UCNN ), innovator of ... premiere national non-profit,patient-advocacy organization, Patient Advocate Foundation (PAF) ... solution across six U.S.,sites as well as home-based ... search and determined,that inContact(R) was the exact solution ...
... HERMOSA BEACH, Calif., April 9 The Massage ... massage location in Manhattan,Beach, California, one block from ... and plans to expand the mini day spa ... held company is currently looking,for investors interested in ...
... wonder if,your doctor personally follows the health advice that ... "Life ... supplemented" Healthcare,Professionals (HCP) Impact Study, the majority ... of the top shared healthy behaviors,being: trying to eat ... taking vitamins and other supplements (72 percent)., Nurses ...
... is a,statement from Matthew L. Myers, President, Campaign for ... have abandoned Ohio,s kids,and put the state,s health at ... the Ohio Tobacco Prevention Foundation. This decision will,guarantee that ... addicted to,tobacco, more Ohio citizens will die prematurely from ...
... Policy Important to Protect Animal, Human Health, ... (AHI) today launched its newly designed "Keeping Animals ... the important,role of public policy in providing animal ... "Americans are becoming more aware of the relationship ...
Cached Medicine News:Health News:Nuvelo Announces Presentations on NU206 and rNAPc2 at 2008 American Association for Cancer Research Annual Meeting 2Health News:Nation's Premiere Patient Advocate Organization Commits to UCN inContact(R) for Entire Group 2Health News:Nation's Premiere Patient Advocate Organization Commits to UCN inContact(R) for Entire Group 3Health News:The Massage Spot Announces Opening of Manhattan Beach Location; Seeks Investors for Growth of 'Affordable Luxury' Mini Day Spa Concept 2Health News:The Massage Spot Announces Opening of Manhattan Beach Location; Seeks Investors for Growth of 'Affordable Luxury' Mini Day Spa Concept 3Health News:Doctors' and Nurses' Wellness Checklist: Healthy Diet, Exercise, Dietary Supplements 2Health News:Doctors' and Nurses' Wellness Checklist: Healthy Diet, Exercise, Dietary Supplements 3
Designed to use all advantages of bipolar technique. C-2600 MP recommended to all specialties that uses the benefits of the bipolar techniques....
Finesse electrosurgical generator (100-120 VAC) utilizes a patented design that integrates the electrosurgical generator and smoke evacuation system into a single compact unit....
The Aaron 800-EU is designed and engineered to be the most reliable and durable desiccator available today....
Sabre 180 is a powerful niche generator....
Medicine Products: